UBS Group
TELO icon

UBS Group’s Telomir Pharmaceuticals TELO Stock Holding History

UBS Group’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.2K Sell
7,959
-1,254
-14% -$1.63K ﹤0.01% 8561
2026
Q1 		$12K Sell
9,213
-4,835
-34% -$6.17K ﹤0.01% 8273
2025
Q4 		$18.7K Sell
14,048
-49,488
-78% -$71.4K ﹤0.01% 7831
2025
Q3 		$88.3K Buy
63,536
+14,805
+30% +$22.3K ﹤0.01% 7209
2025
Q2 		$60.9K Buy
48,731
+33,315
+216% +$77K ﹤0.01% 7613
2025
Q1 		$49.8K Sell
15,416
-9,510
-38% -$41.6K ﹤0.01% 7598
2024
Q4 		$103K Buy
24,926
+21,122
+555% +$99.5K ﹤0.01% 6857
2024
Q3 		$24.4K Sell
3,804
-2,127
-36% -$10.4K ﹤0.01% 7253
2024
Q2 		$28.5K Buy
+5,931
New +$37K ﹤0.01% 7093

Other funds holding TELO

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
WIA
World Investment Advisors Santa Barbara, California $6.04B AUM 22.7% 1-Year Est. Return

UBS Group's TELO Position: Q2 2026 in Review

UBS Group reduced its Telomir Pharmaceuticals (TELO) stake by 14% in Q2 2026, selling an estimated $1.63K and leaving 7,959 shares worth $10.2K. The position accounts for ﹤0.01% of the portfolio, ranked #8561.

UBS Group first reported a position in TELO in Q2 2024 and has held it in 9 quarters since. The position peaked at $103K in Q4 2024. 33 funds tracked by Wall St. Rank hold TELO as of Q2 2026.

  • UBS Group held 7,959 shares of Telomir Pharmaceuticals worth $10.2K as of Q2 2026.
  • UBS Group sold 1,254 Telomir Pharmaceuticals shares in Q2 2026, an estimated $1.63K.
  • Telomir Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8561 holding.
  • UBS Group first reported a position in Telomir Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • UBS Group's Telomir Pharmaceuticals position peaked at $103K in Q4 2024.
  • 33 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.